About Foamix

Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy.
Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne,FMX 103 for the treatment of rosacea,  FMX102 for the treatment of impetigo, and FDX104, our doxycycline foam for the management of acne-like rash, induced by EGFRI anticancer drugs.
Read More

Minocycline Foam

We are developing a topical formulation of minocycline utilizing our proprietary foam technology platform. Our development program consists of three potential indications that we are pursuing: moderate-to-severe acne, impetigo, and rosacea. 
Our phase II results of minocycline foam 4%, applied once-daily, for the treatment of moderate-to-severe acne, showed greater than a 70% reduction in inflammatory acne lesions. We intend to commence Phase III trials for minocycline foam 4% in the United States in 2016


Read More

Recent News

Jun 29

Foamix Pharmaceuticals Appoints David Domzalski as Chief Executive Officer 

Jun 15

Foamix Pharmaceuticals to Present at the 2017 BIO International Convention

Jun 12

Foamix Announces Dosing of First Patient in Phase 3 Rosacea Clinical Trials for FMX103 Minocycline Foam 1.5%